Accrued expenses consisted
of the following:
| | |
March 31, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Accrued excise tax | |
$ | 1,834 | | |
$ | 1,928 | |
| Dividends payable | |
| 5,128 | | |
| 3,778 | |
| Accrued payroll | |
| 329 | | |
| 328 | |
| Accrued clinical trial | |
| 2,088 | | |
| 1,271 | |
| Accrued other | |
| 274 | | |
| 334 | |
| Accrued expenses | |
$ | 9,653 | | |
$ | 7,639 | |
|
Accrued expenses consisted
of the following:
| | |
December 31, | | |
December 31, | |
| | |
2025 | | |
2024 | |
| Accrued excise tax | |
$ | 1,928 | | |
$ | 2,248 | |
| Dividends payable | |
| 3,778 | | |
| 691 | |
| Accrued payroll | |
| 328 | | |
| 204 | |
| Accrued clinical trial | |
| 1,271 | | |
| 43 | |
| Accrued other | |
| 334 | | |
| 527 | |
| Accrued expenses | |
$ | 7,639 | | |
$ | 3,713 | |
|